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Heparin Resistance After Cardiopulmonary Bypass  
 
Francisco J Herrera MD, Mamatha Kadiyala MD, Stanlies D’Souza MD 
  
Department of Anesthesiology, Baystate Medical Center/ Tufts University School of Medicine, Springfield, MA 
Diagnostic Testing 
 
• ACT (activated clotting time)  
• ATIII levels (30-60 min) 
•  High dose thrombin time (more specific for thrombin inhibition) 
• Heparin response curve 
• Heparin level 
Pathophysiology  
 
Preoperative heparin (24-48 hours) is commonly thought to contribute to heparin 
resistance. Heparin-AT complex binds to thrombin and this complex is rapidly 
consumed and cleared via the reticuloendothelial system resulting in a ATIII level 
decline by 5-7%. This decline is thought to be the mechanism by which heparin 
pretreatment increases the incidence of heparin resistance. In addition to ATIII 
deficiency, there are multiple other potential mechanisms that can lead to heparin 
resistance that are both poorly defined and nonspecific.  
Etiology 
  
Deficiency of ATIII decreases the ability of heparin to inhibit thrombin and can be 
either congenital or acquired in etiology. Acquired ATIII deficiency is associated with 
liver disease, malnutrition, nephrotic syndrome, and previous  heparin treatment. 
Other factors related to heparin resistance include IV nitroglycerine, heparin binding 
proteins and factor VIII among others. 
Case Description 
  
A 70 year old male with severe left main coronary artery disease presented for one 
vessel CABG with a baseline ACT of 110. After 30,000 units of intravenous heparin, 
his ACT was 380. An adequate ACT for CPB could not be achieved following 2 
additional doses of 10,000 units of heparin. Adequate anticoagulation was achieved 
with the transfusion of 6 units of fresh frozen plasma and subsequent administration 
of 10,000 units of heparin. His intraoperative course was complicated by significant 
coagulopathy, inadequate reversal with protamine and the requirement for the 
transfusion of blood products. 
Introduction 
 
 Heparin resistance is defined as the inability to achieve an activated clotting time 
(ACT) of >400 seconds after an adequate dose of heparin. Its incidence ranges from 




Therapeutic approaches include 
administering additional heparin, supplement 
ATIII with FFP, supplement ATIII with an ATIII 
concentrate or accept the ACT and proceed 
to CPB without any additional treatment. The 
effectiveness of FFP as treatment in Heparin 
Resistance is limited and no studies have 
shown improvement in clinical outcomes. 
ATIII replacement has been  shown to be 
superior to FFP in increasing ACT, but 
questions remain based on its increased 
cost, lack of clinical outcomes improvement 
and inability to reach the desired ACT in all 
patients with ATIII deficiency. Accepting 
below target ACT for CPB, on fixed heparin 
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Conclusions 
 
•  Identification of patients at risk for HR 
•  Besides ATIII levels, multiple factors affect ACT 
•  The minimum ACT required for safe conduction of CPB remains unknown 
•  A rational approach should be taken to evaluate heparin resistance  
•  Research is needed to confirm clinical benefits in treating heparin resistance 
Alternative Agents 
  
Direct thrombin inhibitor: Bivalirudin (Angiomax) 1.5-2 mg/kg  
followed by 0.5-5 mg/kg/h 
Figure(s) 1 and  2.  Alan Finley MD, Charles Greenberg MD. Heparin Sensitivity and Resistance: 
Management During Cardiopulmonary Bypass. Anesthesia and Analgesia 2013;116(6):1210-1222. 
Copyright 2015 by International Anesthesia Research Society. Used with permission.      
